KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBITDA (2016 - 2025)

Historic EBITDA for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $76.5 million.

  • Emergent BioSolutions' EBITDA rose 1860.47% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 18286.71%. This contributed to the annual value of -$108.7 million for FY2024, which is 8503.58% up from last year.
  • Per Emergent BioSolutions' latest filing, its EBITDA stood at $76.5 million for Q3 2025, which was up 1860.47% from $1.6 million recorded in Q2 2025.
  • Emergent BioSolutions' EBITDA's 5-year high stood at $286.8 million during Q4 2021, with a 5-year trough of -$292.9 million in Q2 2023.
  • Its 5-year average for EBITDA is -$28.2 million, with a median of -$9.5 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 89482.76% in 2021, then plummeted by 223913.04% in 2023.
  • Emergent BioSolutions' EBITDA (Quarter) stood at $286.8 million in 2021, then plummeted by 119.28% to -$55.3 million in 2022, then increased by 20.8% to -$43.8 million in 2023, then surged by 78.31% to -$9.5 million in 2024, then soared by 905.26% to $76.5 million in 2025.
  • Its EBITDA was $76.5 million in Q3 2025, compared to $1.6 million in Q2 2025 and $49.9 million in Q1 2025.